175021-11-1

Basic information

• Product Name: (3,3-dimethoxycyclobutyl)methanol
• Synonyms: (3,3-dimethoxycyclobutyl)methanol;3,3-Dimethoxycyclobutanemethanol
• CAS NO: 175021-11-1
• Molecular Formula: C₇H₁₄O₃
• Molecular Weight: 146.19
• Product Categories: API intermediates
• Mol File: 175021-11-1.mol

Chemical Properties

• Boiling Point: 190℃
• Flash Point: 69℃
• Appearance: /
• Density: 1.06
• Vapor Pressure: 0.151mmHg at 25°C
• Refractive Index: 1.458
• CAS DataBase Reference: (3,3-dimethoxycyclobutyl)methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (3,3-dimethoxycyclobutyl)methanol(175021-11-1)
• EPA Substance Registry System: (3,3-dimethoxycyclobutyl)methanol(175021-11-1)

Safety Data

• Hazardous Substances Data: 175021-11-1(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(3,3-dimethoxycyclobutyl)methanol is utilized as a reagent in various chemical reactions for its ability to participate in a range of organic synthesis processes, contributing to the creation of diverse chemical products.
Used in Pharmaceutical Industry:
In the pharmaceutical sector, (3,3-dimethoxycyclobutyl)methanol serves as a building block for the synthesis of drug molecules, leveraging its unique structure to facilitate the development of new therapeutic agents.
Used in Medicinal Chemistry and Drug Discovery:
(3,3-dimethoxycyclobutyl)methanol is employed as a key component in medicinal chemistry, where its reactivity and structural attributes are harnessed for the discovery and design of novel pharmaceutical compounds with potential therapeutic applications.

InChI:InChI=1/C7H14O3/c1-9-7(10-2)3-6(4-7)5-8/h6,8H,3-5H2,1-2H3

Upstream product

• 545882-50-6 2-[(benzyloxy)methyl]-5,8-dioxaspiro[3.4]octane 
• 695-95-4 methyl 3-oxocyclobutanecarboxylate 
• 23761-23-1 3-oxocyclobutanecarboxylic acid 
• 172324-67-3 3-benzyloxymethyl-cyclobutanone 
• 172324-66-2 3-(benzyloxymethyl)-2,2-dichlorocyclobutanone 
• 98231-07-3 3,3-dimethoxycyclobutanecarboxylic acid methyl ester 

Downstream Products

• 583830-08-4 {[(3,3-dimethoxycyclobutyl)methoxy]methyl}benzene 
• 929911-61-5 (3-hydroxycyclobutyl)methyl benzoate 
• 346425-59-0 (3-oxo-cyclobutyl)methyl benzoate 
• 929911-63-7 ((3-((methylsulfonyl)oxy)cyclobutyl)methyl)benzoate 

Relevant articles and documents

CYCLOALKYLIDENE CARBOXYLIC ACIDS AND DERIVATIVES AS BTK INHIBITORS

The present invention relates to novel cycloalkylidene carboxylic acids and derivatives thereof useful as Bruton tyrosine kinase (BTK) inhibitors. The present disclosure also relates to processes for their preparation, pharmaceutical compositions containing one or more such compounds, and to the use of such compounds and pharmaceutical compositions for the treatment of disorders involving mediation of BTK in humans (Formula I).

COMPOUNDS THAT INHIBIT MCL-1 PROTEIN

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Containing cyclobutane substituent of pyrazines, its composition and use thereof

The invention relates to a cyclobutane substituent group-containing pyrazine compound and application thereof as a drug, and particularly relates to application of the cyclobutane substituent group-containing pyrazine compound in preparing the drug for preventing and treating various influenza viruses. Especially, the invention relates to a compound as shown in a general formula (I) or a stereomer, a geometrical isomer, a tautomer, a nitrogen oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and various variables are defined in the specification. The invention also relates to application of the compound as shown in the general formula (I) or the stereomer, geometrical isomer, tautomer, nitrogen oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug thereof as the drug, and particularly relates to application of the compound as shown in the general formula (I) or the stereomer, geometrical isomer, tautomer, nitrogen oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug thereof as the drug for preventing and treating the influenza viruses.

Containing cyclobutane substituent of pyrazines, its composition and use thereof

The invention relates to a pyrazine compound containing a diethylene substituent and application thereof as a medicine, particularly application thereof to preparation of medicines for preventing and treating various influenza viruses. Particularly, the invention relates a compound of which the general formula I is shown in the specification, or a stereoisomer, a geometrical isomer, a tautomer, a nitrogen oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and all variables are defined in the specification. The invention also relates to application of the compound of which the general formula I is shown in the specification, or the stereoisomer, the geometrical isomer, the tautomer, the nitrogen oxide, the hydrate, the solvate, the metabolite, the pharmaceutically acceptable salt or the prodrug thereof as medicines, particularly application of the compound as a medicine for preventing and treating influenza viruses.

Substituted purine neuraminidase inhibitor and method of use thereof, and use thereof

The invention provides novel substituted purine compounds or stereoisomers, tautomers, nitric oxides, solvates, metabolites and pharmaceutically acceptable salts or prodrugs thereof. The substituted purine compounds are used for inhibiting neuraminidase. The invention also provides a drug composition comprising the compounds, and a method for preventing or treating virus infectious diseases by using the compounds or the drug composition.

CYCLOBUTANE CONTAINING CARBOXYLIC ACID GPR120 MODULATORS

The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR120 G protein-coupled receptor modulators which may be used as medicaments.

OXAZOLIDINONES AS MODULATORS OF MGLUR5

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, agonists and partial agonists for the mGluR5 receptor and may be useful for the treatment of various disorders of the central nervous system.

The discovery and structure-activity relationships leading to CE-156811, a difluorophenyl cyclopropyl fluoroether: A novel potent antibacterial analog derived from hygromycin A

SAR studies and optimization of various modified Hygromycin A fluoroalkyl ethers, which led to the discovery of the highly potent 4′-(2-cyclopropyl- 2-fluoroethyl ether) antibacterial CE-156811 (1) derived from truncation of the ribose ring and difluorination of the phenyl found in Hygromycin A, are discussed.

Pyrazole glucokinase activators

Disclosed herein are pyrazole glucokinase activators of the formula (I) useful for the treatment of metabolic diseases and disorders, preferably diabetes mellitus.

1-(1-CYCLOBUTYL-4-PIPERIDINYL)-1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES WHICH HAVE ACTIVITY ON THE ML RECEPTOR AND THEIR USE IN MEDICINE

Compounds of formula I or a salt thereof are provided wherein R4, R5, R6, Q, L and R are as defined in the description. Uses of the compounds as medicaments and in the manufacture of medicaments for treating psychotic disorders and cognitive impairments are disclosed. The invention further discloses pharmaceutical compositions comprising the compounds.